Pramod Kumar Garg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pramod Kumar Garg has a total of 587 co-authors. Here are the top co-authors by number of shared publications:
Soumya Jagannath Mahapatra
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
19 shared publications- Dm Shalimar
Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India
11 shared publications Ramachandran Thiruvengadam
Center for Maternal and Child Health, Faridabad, Haryana, India
9 shared publicationsNitya Wadhwa
Center for Maternal and Child Health, Faridabad, Haryana, India
8 shared publicationsSaransh Jain
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
8 shared publicationsShallu Midha
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India
8 shared publications
Latest Publications
- 27 April 2026
- Published by Elsevier in Gastroenterology
- Vol. 171 (4) , 610-630
Chronic Pancreatitis: Mechanisms of Inflammation, Pathways of Progression and Emerging Therapeutic Strategies
- 27 April 2026
- Published by Elsevier in Gastroenterology
- Vol. 171 (4) , 610-630
Chronic Pancreatitis: Mechanisms of Inflammation, Pathways of Progression and Emerging Therapeutic Strategies
- 2 April 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 532-538
Pancreatic quantitative sensory testing (P-QST) for pain assessment in Indian patients with chronic pancreatitis
- 2 April 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 532-538
Pancreatic quantitative sensory testing (P-QST) for pain assessment in Indian patients with chronic pancreatitis
- 21 March 2026
- Published by Elsevier in Pancreatology
Development of an experimental model of severe acute pancreatitis with organ failure
- 21 March 2026
- Published by Elsevier in Pancreatology
Development of an experimental model of severe acute pancreatitis with organ failure
- 12 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 215-220
Objective measurement of plasma fluid deficit, sequestration and redistribution of fluid in body compartments in patients with predicted severe acute pancreatitis
- 12 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 215-220
Objective measurement of plasma fluid deficit, sequestration and redistribution of fluid in body compartments in patients with predicted severe acute pancreatitis
- Top Cited Papers
Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)
Background: Recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP) have limited preventive options beyond addressing the underlying aetiology. Statins, due to their anti-inflammatory properties, have been proposed as a potential prophylactic treatment. Objective: We aimed to evaluate whether simvastatin could reduce the recurrence of pancreatitis. Design: At 23 centres, we conducted a triple-blind, randomised, controlled, superiority trial enrolling patients with at least two episodes of RAP or CP flares in the previous 12 months. Participants were randomly assigned to receive simvastatin or placebo for 1 year. The primary endpoint was the recurrence of pancreatitis. The target sample size was 144 patients; however, an interim analysis was planned in the event of slow recruitment. Results: A total of 85 patients (42.1% women) were included in the interim analysis. In the intention-to-treat analysis, no significant differences were observed regarding recurrence: 46.2% simvastatin versus 44.4% placebo; OR 1.07, 95% CI 0.43 to 2.66; p=0.88, or time to recurrence. No statistically significant differences were observed in recurrence in per-protocol analysis (35.5% simvastatin vs 41.9% placebo; OR 0.76, 95% CI 0.27 to 2.12; p=0.60). Development of diabetes mellitus was more frequent in the simvastatin group (4 vs 0 patients; OR not calculable, p=0.04). Conclusion: This trial, evaluating simvastatin versus placebo for the prevention of pancreatitis, did not demonstrate a reduction in recurrence rate, although results might be underpowered due to early termination. The relationship between statins in these patients and new-onset diabetes requires further investigation. Trial registration number: NCT04021498 .
Top Cited PapersSimvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)
Background: Recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP) have limited preventive options beyond addressing the underlying aetiology. Statins, due to their anti-inflammatory properties, have been proposed as a potential prophylactic treatment. Objective: We aimed to evaluate whether simvastatin could reduce the recurrence of pancreatitis. Design: At 23 centres, we conducted a triple-blind, randomised, controlled, superiority trial enrolling patients with at least two episodes of RAP or CP flares in the previous 12 months. Participants were randomly assigned to receive simvastatin or placebo for 1 year. The primary endpoint was the recurrence of pancreatitis. The target sample size was 144 patients; however, an interim analysis was planned in the event of slow recruitment. Results: A total of 85 patients (42.1% women) were included in the interim analysis. In the intention-to-treat analysis, no significant differences were observed regarding recurrence: 46.2% simvastatin versus 44.4% placebo; OR 1.07, 95% CI 0.43 to 2.66; p=0.88, or time to recurrence. No statistically significant differences were observed in recurrence in per-protocol analysis (35.5% simvastatin vs 41.9% placebo; OR 0.76, 95% CI 0.27 to 2.12; p=0.60). Development of diabetes mellitus was more frequent in the simvastatin group (4 vs 0 patients; OR not calculable, p=0.04). Conclusion: This trial, evaluating simvastatin versus placebo for the prevention of pancreatitis, did not demonstrate a reduction in recurrence rate, although results might be underpowered due to early termination. The relationship between statins in these patients and new-onset diabetes requires further investigation. Trial registration number: NCT04021498 .
- Top Cited Papers
- 15 July 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 770-814
International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society
- 15 July 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 770-814
Top Cited PapersInternational Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society
- 28 April 2025
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 44 (6) , 777-798
Endoscopic interventions for managing pancreatic fluid collections associated with acute pancreatitis: A state-of-the-art review (with videos)
Acute pancreatitis is an acute inflammatory disease, which may be associated with pancreatic and peri-pancreatic necrosis and development of (peri)pancreatic fluid collections (PFCs). Interventions in acute pancreatitis have evolved over the years with a paradigm shift from open surgical drainage and necrosectomy to minimally invasive approaches. Depending on the presence of necrosis, the PFCs may be acute necrotic collections or acute pancreatic fluid collections, which evolve over a period of three to four weeks to walled-off necrosis and pseudocysts, respectively. Patients with symptomatic and infected PFCs require drainage. In general, drainage should be delayed beyond three to four weeks when the collection wall has matured and the necrotic debris is liquefied. However, some patients may merit early drainage (within the first three to four weeks), if they have suspected infected pancreatic necrosis and worsening organ dysfunction despite antibiotics and supporting therapy. Endoscopic transmural drainage and necrosectomy have now emerged as the most favored treatment modality in suitable pancreatic collections located predominantly in the lesser sac. Being minimally invasive, per-oral endoscopic direct necrosectomy is as effective as surgical necrosectomy in patients with infected necrotic collections but with fewer adverse events. Percutaneous endoscopic necrosectomy is an important addition to our armamentarium for laterally placed collections as an effective alternative to surgical video-assisted retroperitoneal debridement. The current review provides an overview of the evolution, indications, approaches, techniques and outcomes of endoscopic interventions in the management of pancreatic fluid collections associated with acute pancreatitis. Future direction for better outcomes has been highlighted.
- 28 April 2025
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 44 (6) , 777-798
Endoscopic interventions for managing pancreatic fluid collections associated with acute pancreatitis: A state-of-the-art review (with videos)
Acute pancreatitis is an acute inflammatory disease, which may be associated with pancreatic and peri-pancreatic necrosis and development of (peri)pancreatic fluid collections (PFCs). Interventions in acute pancreatitis have evolved over the years with a paradigm shift from open surgical drainage and necrosectomy to minimally invasive approaches. Depending on the presence of necrosis, the PFCs may be acute necrotic collections or acute pancreatic fluid collections, which evolve over a period of three to four weeks to walled-off necrosis and pseudocysts, respectively. Patients with symptomatic and infected PFCs require drainage. In general, drainage should be delayed beyond three to four weeks when the collection wall has matured and the necrotic debris is liquefied. However, some patients may merit early drainage (within the first three to four weeks), if they have suspected infected pancreatic necrosis and worsening organ dysfunction despite antibiotics and supporting therapy. Endoscopic transmural drainage and necrosectomy have now emerged as the most favored treatment modality in suitable pancreatic collections located predominantly in the lesser sac. Being minimally invasive, per-oral endoscopic direct necrosectomy is as effective as surgical necrosectomy in patients with infected necrotic collections but with fewer adverse events. Percutaneous endoscopic necrosectomy is an important addition to our armamentarium for laterally placed collections as an effective alternative to surgical video-assisted retroperitoneal debridement. The current review provides an overview of the evolution, indications, approaches, techniques and outcomes of endoscopic interventions in the management of pancreatic fluid collections associated with acute pancreatitis. Future direction for better outcomes has been highlighted.
- 10 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 618, 217621
Invasive Salmonella Typhimurium colonizes gallbladder and contributes to gallbladder carcinogenesis through activation of host epigenetic modulator KDM6B
- 10 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 618, 217621
Invasive Salmonella Typhimurium colonizes gallbladder and contributes to gallbladder carcinogenesis through activation of host epigenetic modulator KDM6B
- 25 December 2024
- Published by Elsevier in Pancreatology
- Vol. 25 (2) , 193-199
Subclinical pancreatic exocrine insufficiency is associated with osteopathy in patients with chronic pancreatitis: Implications for management
- 25 December 2024
- Published by Elsevier in Pancreatology
- Vol. 25 (2) , 193-199
Subclinical pancreatic exocrine insufficiency is associated with osteopathy in patients with chronic pancreatitis: Implications for management
- Open Access
- 18 December 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001562
Epidemiology of chronic and acute pancreatitis in India (EPICAP-India): protocol for a multicentre study
Introduction Acute and chronic pancreatitis (CP) are inflammatory conditions of the pancreas that cause local and systemic complications. The epidemiology of these conditions are not well-known in India. Methods and analysis We describe the protocol and procedures of a multicentre study for delineating the epidemiology of pancreatitis in India. We plan to cover 110 000 people across 10 geographically distributed sites in 10 states of India to estimate the burden and risk factors of CP. Trained investigators will make house visits and screen for abdominal pain requiring hospitalisation or pre-diagnosed CP. The screened positive participants will be reviewed by a gastroenterologist to confirm the diagnosis of CP based on radiological imaging. For each case, four controls will be selected and data on risk factors for CP (tobacco, alcohol, family history, metabolic causes) and blood for genetic markers will be collected. Information on the cost of treatment and quality of life will be collected from patients with CP. For estimating incidence of acute pancreatitis (AP), hospital-based sentinel surveillance will be conducted in 10 districts across these 10 states. All hospitals in the district will be contacted to provide a line list of admissions due to acute abdomen including AP for 2 years. The spread of acute abdomen cases will be used to define the catchment area and estimate the denominator population. The line-listed cases with AP living in the catchment area will form the numerator to calculate the incidence. The study will provide critical information for planning pancreatitis-related services in the country. Ethics and dissemination The institutional ethics committee (IECs) at all the participating sites have given their approval for the study. All the participants whose data will be collected will be included after written informed consent. The results may be presented at national or international conferences and will be reported in peer-reviewed publications.
- 18 December 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001562
Open AccessEpidemiology of chronic and acute pancreatitis in India (EPICAP-India): protocol for a multicentre study
Introduction Acute and chronic pancreatitis (CP) are inflammatory conditions of the pancreas that cause local and systemic complications. The epidemiology of these conditions are not well-known in India. Methods and analysis We describe the protocol and procedures of a multicentre study for delineating the epidemiology of pancreatitis in India. We plan to cover 110 000 people across 10 geographically distributed sites in 10 states of India to estimate the burden and risk factors of CP. Trained investigators will make house visits and screen for abdominal pain requiring hospitalisation or pre-diagnosed CP. The screened positive participants will be reviewed by a gastroenterologist to confirm the diagnosis of CP based on radiological imaging. For each case, four controls will be selected and data on risk factors for CP (tobacco, alcohol, family history, metabolic causes) and blood for genetic markers will be collected. Information on the cost of treatment and quality of life will be collected from patients with CP. For estimating incidence of acute pancreatitis (AP), hospital-based sentinel surveillance will be conducted in 10 districts across these 10 states. All hospitals in the district will be contacted to provide a line list of admissions due to acute abdomen including AP for 2 years. The spread of acute abdomen cases will be used to define the catchment area and estimate the denominator population. The line-listed cases with AP living in the catchment area will form the numerator to calculate the incidence. The study will provide critical information for planning pancreatitis-related services in the country. Ethics and dissemination The institutional ethics committee (IECs) at all the participating sites have given their approval for the study. All the participants whose data will be collected will be included after written informed consent. The results may be presented at national or international conferences and will be reported in peer-reviewed publications.